Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (NASDAQ:PGNY) marks its 10-year anniversary on April 1, 2026, celebrating growth in women’s health and family building benefits.
The company highlights support for over 470,000 members, more than 600 employers, coverage of 7.2 million lives, and data-driven clinical outcomes improving IVF and menopause access.
Progyny (Nasdaq: PGNY) announced that company executives will participate in investor conferences in March 2026, including Leerink Partners, Barclays Global Healthcare, and KeyBanc Capital Markets.
Specific sessions: CFO Mark Livingston (fireside chat) on March 10 at 10:40 a.m. ET; CEO Pete Anevski (fireside chats) on March 11 at 1:00 p.m. ET and March 17 at 3:00 p.m. ET; COO Melissa Cummings (panel) on March 17 at 12:00 p.m. ET. Live audiocasts and replays will be available in the Events and Presentations section of Progyny's investor relations website.
Progyny (Nasdaq: PGNY) reported 4Q2025 revenue $318.4M (+6.7% YoY) and FY2025 revenue $1.2887B (+10% YoY). Gross profit was $76.9M in 4Q and $304.5M for FY. Net income was $12.5M (4Q) and $58.5M (FY). Adjusted EBITDA was $51.4M (4Q) and $222.1M (FY).
The company generated $210.2M operating cash flow in 2025, repurchased ~6.5M shares (~$160M), ended year with no debt and ~555 clients.
Progyny (Nasdaq: PGNY) will report fourth quarter and full year 2025 results after market close on February 26, 2026.
The company will host a conference call at 4:45 p.m. ET and publish a press release before the call. Dial‑in numbers, passcode 265484, replay through March 5, 2026, and a live webcast/archive are available on the investor website.
Progyny (Nasdaq: PGNY) expects its fourth quarter and full year results for the period ending December 31, 2025 to be slightly above the financial guidance ranges it provided in November, driven by stronger-than-expected member engagement late in the quarter. The company noted this outlook excludes any non-cash net income impacts tied to the previously announced departure of Michael Sturmer as president. Progyny will discuss these updated expectations at the JP Morgan Healthcare Conference presentation on Jan 13, 2026 at 10:30 a.m. ET, with a live audiocast and replay available on its investor website.
Progyny (Nasdaq: PGNY) published U.S. men’s health research on Nov 20, 2025 exploring attitudes, barriers, and actions around fertility.
Key findings: 75% see fertility as a shared issue, 82% are comfortable discussing fertility with partners, but only 46% of men with fertility issues sought support. Top barriers: fear of diagnosis (64%), cost (56%), and embarrassment (48%). 56% made lifestyle changes after recognizing links between fertility and overall health. Progyny highlights employer opportunity to expand fertility benefits and offers men’s resources including urology networks, testing, and education.
Progyny (Nasdaq: PGNY) announced that CFO Mark Livingston will participate in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.
A live audiocast and replay will be available from the Events and Presentations section of Progyny’s investor website at http://investors.progyny.com.
Progyny (Nasdaq: PGNY) reported 3Q 2025 revenue of $313.3M, up 9.3% year-over-year (or +23% excluding a large non-renewing client). The company posted gross profit $72.8M (+23%), net income $13.9M ($0.15 diluted) and Adjusted EBITDA $55.0M (+18%) with a 17.5% Adjusted EBITDA margin.
Key operational items include ~80 new clients adding ~900,000 lives, near 100% client retention for 2026, ~553 clients and average members ~6.76M. Cash flow was strong with $156.0M operating cash flow for the first nine months and cash & equivalents of $345.2M. The board authorized up to $200M for share repurchases and the company raised full-year 2025 guidance to revenue of $1.263B–$1.278B.
Progyny (Nasdaq: PGNY) will report financial results for the quarter ended September 30, 2025 after market close on Thursday, November 6, 2025.
The company will host a conference call at 4:45 P.M. ET / 1:45 P.M. PT the same day and will issue a press release before the call. U.S. dial-in: 1.866.825.7331 (passcode 265484); international dial-in: 1.973.413.6106. Audio replay available through Thursday, November 13, 2025. Live webcast and archive at http://investors.progyny.com.
Progyny provides employer-focused women’s health and family building benefits and is headquartered in New York City. For investor inquiries: investors@progyny.com.
Progyny (Nasdaq: PGNY) announced a global expansion of benefits to include pregnancy, postpartum, and menopause programs, available to employers starting January 1, 2026. The offerings complement Progyny’s existing global fertility and family building services to provide an integrated continuum across life stages.
Key features include personalized Global Care Advocates, a curated evidence-based knowledge center, country-specific navigator support, and a GDPR-compliant benefits platform. The program supports employees in more than 127 countries with multilingual capabilities.